drugset / Trial / NCT00709826

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

NCT00709826

Phase 2 Completed 109 enrolled Tragara Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare the anti-tumor efficacy of apricoxib and gemcitabine/erlotinib with placebo and gemcitabine/erlotinib in patients with advanced pancreatic cancer.

Timeline

Start
2008-08
Primary completion
2010-06
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject apricoxib Small molecule 400 mg Oral
Background Erlotinib Small molecule 100 mg
Background Gemcitabine Small molecule 1000 mg/m2